Health Care·Biotechnology·$2.2B
Day One Biopharmaceuticals (DAWN) is a biotechnology company focused on developing innovative therapies for patients with rare diseases. Operating in the health care sector, its work is crucial as it addresses unmet medical needs in pediatric populations.
EPS
Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
75%
Avg EPS Surprise
-8.39%
Avg Stock Reaction
-1.23%
In Q4 2025, Day One reported an EPS of $-1.04, significantly missing the estimate of $-0.17. The stock reacted positively the next day, increasing by 2.74%.
Management Promises & Guidance
Analysts expect Day One to report a loss of $0.17 per share on revenues of $54 million for Q1 2026. The company has a history of beating EPS estimates, which could influence market sentiment.
Bull Case
If Day One can exceed revenue expectations and narrow its losses, it may signal strong demand for its therapies, leading to a positive stock reaction.
Bear Case
Conversely, if the company fails to meet revenue expectations or reports wider losses, it could raise concerns about its growth prospects and lead to a negative market reaction.
EPS
$-0.17Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$54MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will the company achieve revenue of at least $54 million?
Meeting or exceeding this revenue target is crucial for demonstrating market demand and operational effectiveness.
Q2
How does the company plan to address its EPS loss of $-0.17?
Understanding management's strategy to reduce losses will be key to assessing future profitability and investor confidence.
Why consensus could be wrong
The consensus may underestimate Day One's ability to capture market share in its niche, given recent advancements in its product pipeline.
Supporting Evidence
The company has a history of beating EPS estimates, which could indicate stronger underlying performance than expected.
Options pricing suggests a lower expected move than historical averages, indicating potential for a larger reaction.
Positive sentiment from recent clinical trial results may not be fully reflected in current estimates.
Key Risk
If revenue exceeds $54 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will indicate whether Day One can sustain growth and improve its financial position.
Bull Confirmed If
Achieving revenue of $54 million or more with a narrower EPS loss would confirm the bull case.
Bear Confirmed If
Reporting revenue below $48 million or an EPS loss greater than $-0.28 would confirm the bear case.
Implied Move
±0.53%
Historical Avg
±2.66%
The options market is pricing a modest move around the earnings report, indicating uncertainty about the results.
Options are pricing a 0.53% move, while the stock has averaged a 2.66% move historically, suggesting a cheap setup.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Day One beats expectations, history suggests the stock could rise around 2.66%, confirming a positive outlook.
In-Line / Cautious
An in-line report may lead to a muted reaction, as investors await further clarity on future guidance.
Miss
If the company misses expectations, the average historical move suggests a potential decline of about 0.29%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026